Will this new drug, approved just last year and launched a couple months ago, bring 10,000% returns for long-term investors?

Compiled list, in order of affection, of our past "Idea of the Month" picks with updated opinions

The annual parade continues — I’m updating my thoughts on the stocks I’ve suggested in the past as “Idea of the Month” investments, and in this installment we’re looking at what are mostly dividend-growth stocks: income ideas, but not stocks that have particularly huge current dividends (those “bigger yielders” were covered in Part one here). […]

The markets are debt-obsessed once again, I’m afraid — not corporate debt, as they were in 2008 and 2009 when any company with leveraged was thrown out the window, but gummint debt. I don’t know whether this will be a real “reckoning” for the US government, when we really take stock of our obligations and […]

Much of the time I end up profiling companies in this space that are quite small, relatively unknown, and perhaps a bit difficult to trade. I’m sure I’ll continue to do that in the future as interesting companies cross my radar, but today, with my level of uncertainty about the global economy fairly high, I […]